Drug shows promise in slowing effects of Alzheimer's disease

Newsy

18 Jul 2023 0 shares 2 views

Drug shows promise in slowing effects of Alzheimer's disease

Drug shows promise in slowing effects of Alzheimer's disease

Newsy

Published 18 Jul 2023

ViewAnother drug is showing promise for those at risk of Alzheimer's disease.

Donanemab, produced by Eli Lilly, could be on the market by the end of the year.

A report released in JAMA Monday found the drug slowed cognitive decline by about 35% in a phase 3 clinical trial.

You may recall that just weeks ago the FDA...

You might like

Related news coverage

Second Alzheimer's slowing drug to seek approval in the US

Upworthy 18 Jul 2023

Donanemab has proven to slow disease progression by several months in some patients but has also shown serious side effects...

Side-effects of 'turning point' Alzheimer's drug donanemab as disease slowed in clinical trial
Tamworth Herald 18 Jul 2023
Newspaper review: 'Breakthrough Alzheimer's drug' and Greek wildfires
BBC News 17 Jul 2023
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern
SeattlePI.com 17 Jul 2023
Eli Lilly's donanemab slows early stages of Alzheimer's disease, study shows
USATODAY.com 17 Jul 2023

Advertisement

More coverage

New weight loss drug retatrutide shows promise in trial, doctors say

Newsy 13 Jul 2023

ViewMore than half of the world population will be obese by 2035, according to the 2023 World Obesity..

FDA makes Alzheimer's drug Leqembi more widely available for use
Newsy 06 Jul 2023
Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it
SeattlePI.com 06 Jul 2023